➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 211651

Email this page to a colleague

« Back to Dashboard

NDA 211651 describes TALZENNA, which is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug. Additional details are available on the TALZENNA profile page.

The generic ingredient in TALZENNA is talazoparib tosylate. Two suppliers are listed for this compound. Additional details are available on the talazoparib tosylate profile page.
Summary for 211651
Ingredient:talazoparib tosylate
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 211651
Generic Entry Date for 211651*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 211651
Suppliers and Packaging for NDA: 211651
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TALZENNA talazoparib tosylate CAPSULE;ORAL 211651 NDA Pfizer Laboratories Div Pfizer Inc 0069-0296 0069-0296-30 30 CAPSULE in 1 BOTTLE (0069-0296-30)
TALZENNA talazoparib tosylate CAPSULE;ORAL 211651 NDA Pfizer Laboratories Div Pfizer Inc 0069-1195 0069-1195-30 30 CAPSULE in 1 BOTTLE (0069-1195-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 0.25MG BASE
Approval Date:Oct 16, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 16, 2023
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Free Forever TrialPatent Expiration:Oct 20, 2031Product Flag?YSubstance Flag?YDelist Request?
Patent:⤷  Free Forever TrialPatent Expiration:Oct 19, 2029Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.